Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia
Open Access
- 18 May 2007
- Vol. 109 (11), 2291-2298
- https://doi.org/10.1002/cncr.22662
Abstract
BACKGROUND. The prevalence of chronic lymphocytic leukemia (CLL) increases with age. Although chemoimmunotherapy (CIT) has dramatically improved response rates in patients with CLL, some CIT regimens are not well tolerated by many patients ≥70 years of age. METHODS. Sixty‐four previously untreated patients with CLL and serum creatinine 2), cyclophosphamide (600 mg/m2), and rituximab (375 mg/m2). The authors measured performance status at study entry and used age, weight, and baseline creatinine to calculate creatinine clearance (CrCl). RESULTS. Eighteen of 64 (28%) patients were ages ≥70 years. Although individuals ages ≥70 years were more likely to have delayed treatment cycles (28% vs 7%; P = .03), there were no significant differences in the number of cycles administered, need for dose reductions, or grade 3–4 hematologic, infectious, or other toxicities. No significant differences in overall response rate, complete response rate, or progression‐free survival were observed by age. Twenty‐five (39%) patients had a CrCl < 70 mL/min (range, 34–67). Although individuals with CrCl < 70 were more likely to require dose reduction (24% vs 5%; P = .05), there were no significant differences in the number of cycles administered or grade 3–4 hematologic, infectious, or other toxicities. No significant difference in overall response rate, complete response rate, or progression‐free survival were observed between patients with CrCl ≥ 70 mL/min and those with CrCl < 70 mL/min. CONCLUSIONS. In this clinical trial, the PCR regimen was well tolerated by older patients and individuals with CrCl ≤ 70. The efficacy of PCR was not significantly affected by age or renal function. These findings suggest PCR may be a good therapeutic option for older patients and those with modestly decreased renal function. Cancer 2007; 109:2291–8. © 2007 American Cancer Society.Keywords
This publication has 32 references indexed in Scilit:
- Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaBlood, 2006
- Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2)Blood, 2006
- Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemiaBlood, 2005
- Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2005
- Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011Blood, 2005
- Chronic Lymphocytic Leukemia (CLL): First-Line TreatmentHematology-American Society Hematology Education Program, 2005
- The clinical and epidemiological burden of chronic lymphocytic leukaemiaEuropean Journal of Cancer Care, 2004
- Conventional Dose Fludarabine-based Regimens are Effective but have Excessive Toxicity in Elderly Patients with Refractory Chronic Lymphocytic LeukemiaLeukemia & Lymphoma, 2003
- Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)Blood, 2002
- Pentostatin in Refractory Chronic Lymphocytic Leukemia: A Phase II Trial of the European Organization for Research and Treatment of CancerJNCI Journal of the National Cancer Institute, 1990